Login
Login     |     Register     |     Recover Username/Password

General Investing

In European Economy, Even the Price of Bananas is Going Bananas

June 22, 2010

The European debt crisis and shaky economy are not only affecting foreign exchange rates and raising borrowing costs, but they are also taking a toll on farm products companies, such as Chiquita Brands International (CQB).

“They have 40% of their business out of Europe, so clearly what’s going on in Europe is having a somewhat dramatic impact on expectations for the company in two ways,” said Scott A. Mushkin, a managing director and senior research analyst at Jefferies & Company. “One is currency, and the second is that they sell premium bananas. And as the European economy starts to slow significantly, that would hurt them on sales as well.”

Although Mushkin is optimistic the company will be better positioned following a European recovery — thanks to Chiquita’s proactive stance to try to keep its European bananas profitable — he is wary of the immediate impact the European crisis will have on the company.

“Bananas are priced in dollars, and so supply will adjust because of what’s going on with the euro. So that’s one issue, the euro. But the other issue is what’s going on with the economy over there, and that clearly is going to hurt demand for Chiquita’s bananas because of premium pricing,” Mushkin said. “Clearly what’s going on in the economies over there is going to impact particularly Chiquita because of the 20% premium we estimate they get on their bananas because of the brand. So if the economies roll over in Europe, or if they never get off of the mat, if you think they are going to do poorly, that would be a problem.”


TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now